PF-Atlas › Clinical Trials › NCT02951182

A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis

TEZ · Phase 2

Registry ID

NCT02951182

Phase

Phase 2

Status

Completed

Drug / intervention

TEZ

Sponsor

Vertex Pharmaceuticals Incorporated

Start

2016-10

Enrollment

Locations

About this trial

This is a Phase 2, randomized, double-blind, placebo- and active-controlled, parallel group, multicenter study to evaluate the safety, tolerability, and efficacy of VX-440 in dual and triple combination with tezacaftor (TEZ; VX-661) and ivacaftor (IVA; VX-770) in subjects with cystic fibrosis (CF) who are homozygous for the F508del mutation of the CF transmembrane conductance regulator (CFTR) gene (F508del/F508del), or who are heterozygous for the F508del mutation and a minimal function (MF) CFTR mutation not likely to respond to TEZ and/or IVA therapy (F508del/MF).

View NCT02951182 on ClinicalTrials.gov →

Explore related

All TEZ trials All IPF trials

Medical disclaimer. This page summarizes public trial data for NCT02951182 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.